This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
Epistemonikos ID: 686b07f6a848952bdc97f5e94cfc596050ae0e1a
First added on: Jun 21, 2025